IMU Biosciences raises £11.5 million in Series A funding to revolutionise immune powered precision medicine

We’re delighted to share that IMU Biosciences, a Kfund portfolio company, has raised an £11.5 million Series A round, led by Molten Ventures.

Our history with IMU goes back to 2020, when we invested in Melio, a B2C company co-founded by Mario Cantero and Will Stoddart.

Melio ended up pivoting into IMU Biosciences 2011, after Kings College researchers Tom Hayday and Adam Laing also joined the company. We were supporters of the team through this transition and we couldn’t be happier for Mario and the extended team, who were resilient and patient while navigating the ups and downs of company building.

IMU is revolutionising immune powered precision medicine, by coupling deep, systems-level immune profiling with a proprietary AI platform to build a uniquely detailed immune atlas spanning the breadth of human health and disease.

IMU’s platform has application across multiple high-growth areas, including immune-oncology, cell therapy, autoimmune disorders and transplantation.

IMU is the definition of a mission-driven company and we couldn’t be more excited about the road ahead.

For more information, please read the press release here.

No items found.
Twitter
Facebook

We’re delighted to share that IMU Biosciences, a Kfund portfolio company, has raised an £11.5 million Series A round, led by Molten Ventures.

Our history with IMU goes back to 2020, when we invested in Melio, a B2C company co-founded by Mario Cantero and Will Stoddart.

Melio ended up pivoting into IMU Biosciences 2011, after Kings College researchers Tom Hayday and Adam Laing also joined the company. We were supporters of the team through this transition and we couldn’t be happier for Mario and the extended team, who were resilient and patient while navigating the ups and downs of company building.

IMU is revolutionising immune powered precision medicine, by coupling deep, systems-level immune profiling with a proprietary AI platform to build a uniquely detailed immune atlas spanning the breadth of human health and disease.

IMU’s platform has application across multiple high-growth areas, including immune-oncology, cell therapy, autoimmune disorders and transplantation.

IMU is the definition of a mission-driven company and we couldn’t be more excited about the road ahead.

For more information, please read the press release here.